Biotech | August 08, 2022
Biocon Sdn. Bhd. enters Malaysia Book of Records
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
This facility will design & develop instruments, perform product reliability performance testing and verification
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Subscribe To Our Newsletter & Stay Updated
